BIOLINERX | Investor Information | 2014 Press releases

2014 Press releases

Receive e-mail alerts |

Rss feeds

Keyword search

2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012

Date	Title
12/23/14	BioLineRx Out-Licenses Novel Skin Lesion Treatment to Omega Pharma
12/16/14	BioLineRx and Major Global Pharmaceutical Company Form Strategic Collaboration for Screening and Development of Novel Drug Candidates
12/12/14	BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform
12/08/14	BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH Conference
11/10/14	BioLineRx Reports Third Quarter 2014 Financial Results
11/05/14	BioLineRx Announces Successful Final Results of Phase 1/2 Study for Novel Celiac Treatment
11/03/14	BioLineRx to Report Third Quarter 2014 Results on November 10, 2014
11/03/14	BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy and Strong Safety Profile
10/31/14	BioLineRx Reports Publication in Peer Review Journal of Results from Previous Phase 1/2 Trial for BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial Infarction
09/17/14	BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations
09/03/14	BioLineRx Doses First Patient for BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment
09/02/14	BioLineRx to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York
08/21/14	BioLineRx Receives Notice of Allowance for US Patent on BL-7010 Covering Use of Novel Polymer in Prevention of Gluten Toxicity
08/06/14	BioLineRx Reports Second Quarter 2014 Financial Results
07/30/14	BioLineRx to Report Second Quarter 2014 Results on August 6, 2014
07/16/14	BioLineRx Announces Results from Phase 1/2 Study for Celiac Treatment
06/23/14	BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain
06/16/14	BioLineRx Receives Approval to Commence Phase 1 Trial for Novel Stem Cell Mobilization Treatment
06/11/14	BioLineRx Receives Notice of Allowance for US Patent Covering Novel Treatment for Celiac Disease
05/30/14	BioLineRx Enters into Share Purchase Agreement with Lincoln Park Capital
05/20/14	BioLineRx Reports First Quarter 2014 Financial Results
05/15/14	BioLineRx to Report First Quarter 2014 Results on May 20, 2014
04/10/14	BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment
03/17/14	BioLineRx Reports Year End 2013 Financial Results
03/14/14	BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 in Immunotherapy
03/11/14	BioLineRx to Report Fourth Quarter and Year End 2013 Results on March 17, 2014
03/10/14	BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study for Novel Celiac Treatment
03/07/14	BioLineRx Closes $24.1 Million Underwritten Public Offering of its American Depositary Shares
03/05/14	BioLineRx to Present at the Annual ROTH Growth Stock Conference in California
03/04/14	BioLineRx Prices $21.0 Million Underwritten Public Offering of its American Depositary Shares
03/03/14	BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
02/24/14	BioLineRx Appoints Dr. Sandra Panem to Board of Directors
02/12/14	BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia
02/03/14	BioLineRx to Present at the 2014 BIO CEO & Investor Conference in New York on February 10
01/23/14	BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment
01/21/14	BioLineRx Receives Approval to Commence Pivotal Trial for Novel Skin Lesion Treatment
01/13/14	BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment
01/08/14	BioLineRx and JHL Biotech to Collaborate on Type 1 Diabetes Antibody Treatment
01/07/14	BioLineRx to Present at Biotech Showcase Conference in San Francisco